Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
CD53 CRISPR/Cas9 KO Plasmid (m): sc-419561
- Target species: mouse
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- CD53 CRISPR/Cas9 Knockout (KO) Plasmid (m) is a pool of plasmids, each encoding Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed for maximum knockout efficiency using sequences derived from the GeCKO v2 library
- gRNA sequences direct Cas9 to induce site-specific double-strand breaks (DSBs) in the CD53 genomic locus, resulting in gene knockout through non-homologous end joining (NHEJ)
- The puromycin resistance and RFP genes are flanked by LoxP sites, enabling removal of selection markers via Cre recombinase (Cre Vector: sc-418923) after establishing stable knockout cell lines
- Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: CD53 Antibody (B-12): sc-390185
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
CD53 CRISPR/Cas9 KO Plasmid (m) | sc-419561 | 20 µg | $397.00 |
Overview
Cd53 encodes CD53, a tetraspanin cell-surface glycoprotein enriched on leukocytes that helps organize membrane microdomains and coordinate receptor signaling. CD53 participates in immune cell adhesion, migration, and activation by modulating integrin function and associating with signaling complexes that influence cytoskeletal remodeling and downstream kinase pathways. In mouse models, CD53 expression patterns and function are closely linked to B cell and T cell responses, antigen presentation, and inflammatory signaling networks. Dysregulated tetraspanin organization, including altered CD53-dependent interactions, is frequently studied in contexts of immune dysfunction and hematopoietic cell biology.
CD53 CRISPR/Cas9 KO Plasmid (m) is a pool of plasmids designed for targeted disruption of the Cd53 gene in mouse cell lines. Each plasmid co-expresses a unique single guide RNA (sgRNA) targeting a distinct site within the Cd53 together with the Streptococcus pyogenes Cas9 nuclease. The plasmids also encode GFP, allowing fluorescent identification and enrichment of successfully transfected cells by fluorescence microscopy or flow cytometry.
The multi-guide design increases the likelihood of generating insertions or deletions (indels) that disrupt the Cd53 open reading frame following Cas9-mediated double-strand break formation. DNA breaks introduced by the CRISPR/Cas9 system are repaired through endogenous non-homologous end joining (NHEJ) pathways, frequently resulting in frameshift mutations that abolish CD53 protein expression.
This CRISPR knockout system enables efficient generation of Cd53-deficient cell models for investigation of CD53 signaling, functional genomics studies, cancer biology research, and evaluation of therapeutic responses in human cell lines.
Key Features
- sgRNAs targeting Cd53 exon(s) critical for CD53 function
- Co-expression of SpCas9 and sgRNA from a single plasmid for simplified delivery
- GFP reporter for identification of transfected cells
- Pool of plasmids targeting multiple Cd53 genomic sites to improve knockout efficiency
- Compatible with delivery by transfection
Design Variants
CRISPRs +/- HDRs
- gRNAs encoded by CD53 CRISPR/Cas9 KO Plasmid (m) and CD53 CRISPR/Cas9 KO Plasmid (m2) target distinct sites within the Cd53 locus. One or both targeting designs may be available. See Related Products for availability.
- HDR donor constructs encoded by CD53 HDR Plasmid (m) and CD53 HDR Plasmid (m2) contain a puromycin resistance cassette and an RFP reporter flanked by Cd53 homology arms to support homology-directed repair at defined Cd53 target sites corresponding to the CRISPR/Cas9 KO designs. HDR donor availability may vary. See Related Products for availability.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.